Navigation Links
Inspire Announces Presentations at Two European Scientific,Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis Society (ECFS) Conference being held June 13-16, 2007 in Belek, Turkey.

The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily

   Bilastine with Cetirizine and Placebo for the Treatment of Seasonal

   Allergic Rhinitis

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Treatment with Bilastine Improves Symptoms in Patients with

   Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy

   and Safety of Once Daily Bilastine with Desloratadine and Placebo

   for the Treatment of Seasonal Allergic Rhinitis)

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines

   Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -

   Evidence of High Lung Delivery and Minimal Systemic Exposure

   Poster presentation on Thursday and Friday, June 14-15, 2007 and

   oral presentation on Thursday, June 14, 2007


-- Reactive Airway Disease and
 Cystic Fibrosis: a Retrospective

   Analysis of the Safety and Tolerability with Denufosol Inhalation

   Solution

   Poster presentation on Thursday, June 14, 2007 and guided poster

   tour on Friday, June 15, 2007

The posters from these presentations will be available following each related conference on Inspire's website, www.inspirepharm.com, in the Research & Development section, under Science & Technology.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, s uccess of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.

Contact

Investor Contacts:
Inspire Pharmaceuticals, Inc.
Jenny Kobin,
VP, Investor Relations and Corporate Communications
919-941-9777, Extension 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, Extension 14


'"/>




Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TOKYO , April 28, 2016 /PRNewswire/ ... Ahuja , George Phillips und ... wachsenden Unternehmens    ArisGlobal®, ein ... Life Sciences, gab heute bekannt, dass neue ... wachsenden Unternehmens gestoßen sind, die vielfältige Erfahrungen ...
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks ... impact on public health. The World Veterinary Association (WVA) and the World Organization ... selected continuing education with a One Health focus, which emphasizes how veterinarians pursue ...
(Date:4/30/2016)... ... ... all of us, but there are things we can do to improve the odds of staying ... and more that there are simple, yet important steps that can be taken to maintain good ... recommends for her patients include;, , exercise , healthy ...
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its Graduate Business Programs ... be expanding due to high demand: Master of Business Administration (MBA), Master of Organizational ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
Breaking Medicine News(10 mins):